Objectives: To evaluate the diagnostic accuracy of perfluorobutane contrast-enhanced ultrasonography (CEUS) for hepatocellular carcinoma (HCC) and to explore how accuracy can be improved compared to conventional diagnostic criteria in at-risk patients.

Methods: A total of 123 hepatic nodules (≥ 1 cm) from 123 at-risk patients who underwent perfluorobutane CEUS between 2013 and 2020 at three institutions were retrospectively analyzed. Ninety-three percent of subjects had pathological results, except benign lesions stable in follow-up images. We evaluated presence of arterial phase hyperenhancement (APHE), washout time and degree, and Kupffer phase (KP) defects. KP defects are defined as hypoenhancing lesions relative to the liver in KP. HCC was diagnosed in two ways: (1) Liver Imaging Reporting and Data System (LI-RADS) criteria defined as APHE and late (≥ 60 s)/mild washout, and (2) APHE and Kupffer (AK) criteria defined as APHE and KP defect. We explored grayscale features that cause misdiagnosis of HCC and reflected in the adjustment. Diagnostic performance was compared using McNemar's test.

Results: There were 77 HCCs, 15 non-HCC malignancies, and 31 benign lesions. An ill-defined margin without hypoechoic halo on grayscale applied as a finding that did not suggest HCC. Regarding diagnosis of HCC, sensitivity of AK criteria (83.1%; 95% confidence interval [CI]: 72.9-90.7%) was higher than that of LI-RADS criteria (75.3%; 95% CI: 64.2-84.4%; p = 0.041). Specificity was 91.3% (95% CI: 79.2-97.6%) in both groups.

Conclusion: On perfluorobutane CEUS, diagnostic criteria for HCC using KP defect with adjustment by grayscale findings had higher diagnostic performance than conventional criteria without losing specificity.

Key Points: • Applying Kupffer phase defect instead of late/mild washout and adjusting with grayscale findings can improve the diagnostic performance of perfluorobutane-enhanced US for HCC. • Adjustment with ill-defined margins without a hypoechoic halo for features unlikely to be HCC decreases false positives for HCC diagnosis using the perfluorobutane-enhanced US. • After adjustment with grayscale findings, the sensitivity and accuracy of the APHE and Kupffer criteria were higher than those of the LI-RADS criteria; specificity was 91.3% for both.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00330-022-08900-6DOI Listing

Publication Analysis

Top Keywords

kupffer phase
12
li-rads criteria
12
diagnostic performance
12
grayscale findings
12
hcc
9
criteria
9
hepatocellular carcinoma
8
diagnostic criteria
8
perfluorobutane ceus
8
benign lesions
8

Similar Publications

Potential for contrast-enhanced intraoperative ultrasonography with the Kupffer phase to improve and guide therapeutic strategies for hepatocellular carcinoma.

Quant Imaging Med Surg

December 2024

Department of General Surgery, Beijing Hospital, National Centre of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.

Article Synopsis
  • CE-IOUS is a promising technique for improving detection of hidden HCC tumors during surgery, particularly for patients with cirrhosis, where traditional imaging may miss some lesions.
  • A study involving 25 patients showed that CE-IOUS has a high sensitivity for detecting HCC lesions (96.5%), comparable to MRI and CEUS, suggesting its effectiveness in surgical settings.
  • The findings indicate that utilizing CE-IOUS could enhance surgical strategies for HCC by identifying additional lesions that need to be addressed, potentially leading to better patient outcomes.
View Article and Find Full Text PDF

Hepatocellular carcinoma (HCC) is the most common form of hepatic malignancy, with high mortality rates recorded globally. Early detection through clinical biomarkers, medical imaging and histological assessment followed by rapid intervention are integral for positive patient outcomes. Although contrast-enhanced computed tomography scans and magnetic resonance imaging are recognised as the reference standard for the diagnosis and staging of HCC in international guidelines, ultrasound (US) examination is recommended as a screening tool for patients at risk.

View Article and Find Full Text PDF
Article Synopsis
  • The study evaluates the effectiveness of Sonazoid-CEUS in diagnosing hepatocellular carcinoma (HCC) in cirrhotic patients, comparing guidelines from KLCA-NCC 2022 and APASL 2017.
  • Results indicate that the KLCA-NCC 2022 guidelines offer high sensitivity (96.2%) and impressive specificity (93.8%), while APASL 2017 shows higher sensitivity (97.8%) but lower specificity (46.9%).
  • Overall, Sonazoid-CEUS guided by KLCA-NCC 2022 is highlighted as a promising tool for HCC diagnosis, offering strong predictive values and accuracy in clinical settings.
View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to create and validate a prediction model that identifies microvascular invasion (MVI) in patients with single hepatocellular carcinoma (HCC) tumors smaller than or equal to 5 cm using ultrasound and biochemical indicators.
  • Data was collected from 318 patients over 18 months, utilizing various ultrasound techniques and biochemical tests to identify independent predictors of MVI, which were then analyzed through logistic regression.
  • Key findings revealed specific ultrasound features and a biochemical marker (PIVKA-II) were strongly associated with MVI, and the combined model demonstrated high accuracy and reliability for preoperative predictions.
View Article and Find Full Text PDF

Objective: To investigate Sonazoid contrast-enhanced ultrasound (CEUS) features of intrahepatic cholangiocarcinoma (ICC) based on liver backgrounds and tumor sizes.

Methods: A retrospective analysis was conducted on patients with histopathologically diagnosed ICC at two centers. Patients underwent Sonazoid CEUS examination at a dose of 0.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!